EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Treatment-resistant Parkinson's disease psychosis responding to xanomeline-trospium: A case report

Andrew Farah, Karen Timbrook-Dillow, Heather Garrison

Clinical Parkinsonism & Related Disorders · 2026 · 15 · 100497

DOI: 10.1016/j.prdoa.2026.100497 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Parkinsonism & Related Disorders, 2026. Verfasst von Andrew Farah und 2 weiteren Autor:innen. Beteiligte Einrichtung: High Point University, High Point, North Carolina 27268, USA. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report the case of an 83-year-old male with Parkinsonism and severe psychosis characterized by persistent daytime and nighttime hallucinations associated with marked fear and distress. His psychosis failed to respond to therapeutic trials of quetiapine, brexpiprazole, and pimavanserin. He was referred specifically for a trial of clozapine therapy, which the patient and caregiver declined due to its risk profile. Treatment with xanomeline-trospium was initiated at 50/20 mg twice daily and resulted in substantial improvement, including resolution of nighttime hallucinations within two weeks. He further achieved a near complete resolution of psychotic symptoms within three weeks of a dose escalation to 100/20 mg twice daily. To our knowledge, this is the first published case of Parkinson's disease psychosis successfully treated with xanomeline-trospium, a novel M1/M4 muscarinic receptor agonist-based therapy. The patient's psychosis proved refractory to three pharmacologically distinct therapies-quetiapine, a low-affinity, rapidly dissociating dopamine D2 receptor antagonist; brexpiprazole, a dopamine D2 partial agonist; and pimavanserin, a selective 5-HT2A receptor inverse agonist-before improving with xanomeline-trospium, whose antipsychotic effects are mediated through central M1/M4 muscarinic receptor agonism. This case supports the further investigation of muscarinic receptor agonism as a therapeutic strategy for Parkinson's disease psychosis.

Schlagwörter

Stichwörter der Autor:innen

HallucinationsMuscarinic receptor agonistsParkinson's disease psychosis (PDP)Xanomeline-trospium

Autor:innen und Institutionen

  • High Point University, High Point, North Carolina 27268, USA.

Zitieren

APA

Farah, A., Timbrook-Dillow, K., & Garrison, H. (2026). Treatment-resistant Parkinson's disease psychosis responding to xanomeline-trospium: A case report. Clinical Parkinsonism & Related Disorders, 15, 100497. https://doi.org/10.1016/j.prdoa.2026.100497

Vancouver

Farah A, Timbrook-Dillow K, Garrison H. Treatment-resistant Parkinson's disease psychosis responding to xanomeline-trospium: A case report. Clinical Parkinsonism & Related Disorders. 2026;15:100497. doi:10.1016/j.prdoa.2026.100497

BibTeX
@article{Farah2026,
  author = {Farah, Andrew and Timbrook-Dillow, Karen and Garrison, Heather},
  title = {Treatment-resistant Parkinson's disease psychosis responding to xanomeline-trospium: A case report},
  journal = {Clinical Parkinsonism & Related Disorders},
  year = {2026},
  volume = {15},
  pages = {100497},
  doi = {10.1016/j.prdoa.2026.100497}
}
Kostenlos starten →